Radiopharmaceutical Development of Molecular and Targeted Radiotherapy
Radiopharmaceuticals are transforming oncology by delivering radioactive isotopes directly to tumors with high precision. This enables both diagnostic and therapeutic applications, the foundation of theranostics.
At Oncodesign Services, we support biotechs and pharma in accelerating the development of innovative radiopharmaceuticals. With deep expertise in oncology and nuclear medicine, we provide an integrated approach that covers every stage of molecular radiotherapy (MRT) / targeted radiotherapy (TRT), from discovery to IND/IMPD-enabling studies.
Radiopharmaceutical Development Expertise
Radiopharmaceuticals combine the power of radiation with the selectivity of targeted molecules. They enable both diagnostic imaging and therapeutic applications.
Our scientists combine radiochemistry, molecular biology, pharmacology and imaging to design, test and optimize compounds that improve patient outcomes while reducing risk for biotech programs.
Unlike many CROs focused on single aspects of radioligand therapy, Oncodesign Services offers end-to-end support including:
Through our platform, a wide range of alpha, beta, gamma and positron emitter isotopes are supported. We constantly work to ensure radionuclide availability.
Read our article on radionuclide supply: HERE
Molecular Radiotherapy / Targeted Radiotherapy
Our teams specialize in targeted radiotherapy. An approach that uses radiopharmaceuticals to selectively destroy cancer cells while sparing healthy tissue. By leveraging molecular targets, receptor binding, and radioligand design, we ensure precise delivery of therapeutic radioisotopes.
Unlike external beam radiation therapy, where radiation is directed from outside the body, targeted radionuclide therapy involves the internal delivery of radiation. The radiopharmaceutical is usually administered intravenously and circulates through the bloodstream, selectively binding to cancer cells. Once the radiopharmaceutical has bound to the cancer cells, it irradiates the tumor area. These particles have a short range, allowing for localized damage to the targeted cancer cells and not irradiate the surrounding healthy tissues.
The development of radiopharmaceuticals inquires several stages including discovery (to identify and optimize a target that may be treated using radiopharmaceuticals) and preclinical studies (to evaluate the safety, pharmacokinetics and efficacy of the radiopharmaceutical candidate).
This seamless integration ensures faster, de-risked development for biotech innovators.
Oncodesign Services has a unique offer dedicated to preclinical evaluation of radiopharmaceuticals, with a combination of our skills in radiochemistry and in vivo imaging in order to assess systemic radiotherapy efficacy.
With preferred field expert partners, we enable faster and cost-optimized development of your therapeutic, diagnostic or theranostic entity from bioconjugation and radiolabeling up to IND-enabling studies, and even first-in-human.
Theranostics: from bench to bedside
With deep expertise in theranostics, we help our partners bridge the gap between diagnostic radiopharmaceuticals and therapeutic applications. This seamless approach accelerates drug development, improves patient stratification, and enhances the likelihood of clinical success.
Why Oncodesign Services?
- End-to-end radiopharmaceutical R&D capabilities
- State-of-the-art radiochemistry and preclinical imaging facilities
- Experience in oncology, nuclear medicine, and translational science
- Flexible partnership models to match your program’s needs
Oncodesign Services is your partner of choice for advancing radiopharmaceuticals, from early discovery through clinical development, in molecular and targeted radiotherapy, radioligand therapy, and theranostics.
Need advice for your radiopharmaceutical development? Contact us today!
